Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

Abstract:

:In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen patients received a continuous infusion of 21 mg idarubicin/m2/day for 2 consecutive days in addition to the standard preparative regimen. Thirteen patients served as a historical control group. The 2-year disease-free survival (DFS) of 82% in the study group was significantly (P = 0.047) better compared to 46% DFS in the control group. The relapse rate (RR) was also significantly lower (7% vs 45%; P = 0.035) in the study group. The median time to reach a white cell count (WCC) of 0.5 x 10(9)/l was 20 days in the study group vs 17 days (P = NS) in the control group. The median time until recovery of the platelet counts to 20 x 10(9)/l was 152 days in the study group vs 57 days (P = NS) in the control group. The hypoplasia in the study group resulted in a trend towards a higher need for transfusions: a median number of 38 units of erythrocytes vs 23 units in the control group (P = NS) and 23 units of platelet vs 18 units in the control group (P = NS). This pilot study suggests that addition of idarubicin to the standard conditioning regimens may improve DFS and overall survival (OS) of patients with AML treated with ABMT in CR1. These results should be confirmed in a prospective randomized study.

journal_name

Bone Marrow Transplant

authors

Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

doi

10.1038/sj.bmt.1701279

subject

Has Abstract

pub_date

1998-07-01 00:00:00

pages

13-9

issue

1

eissn

0268-3369

issn

1476-5365

journal_volume

22

pub_type

临床试验,杂志文章
  • Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.

    abstract::A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705665

    authors: Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

    更新日期:2007-06-01 00:00:00

  • Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.

    abstract::Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

    更新日期:1996-09-01 00:00:00

  • Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.

    abstract::Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We analyzed the clinical outcome of ABO incompatibility after allogeneic PBSCT. A total of 89 consecutive adult patients with hematological dise...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704816

    authors: Kim JG,Sohn SK,Kim DH,Baek JH,Lee KB,Min WS,Kim CC,Lee MH,Lee JJ,Chung IJ,Kim HJ,Lee JW

    更新日期:2005-03-01 00:00:00

  • Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.

    abstract::To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD proph...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703916

    authors: Verma A,Devine S,Morrow M,Chen YH,Mihalov M,Peace D,Stock W,Pursell K,Wickrema A,Yassine M,Jessop E,van Besien K

    更新日期:2003-05-01 00:00:00

  • Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.

    abstract::Stroke is an important complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nevertheless, few studies have been published to analyzed the occurrence and prognosis of stroke after allo-HSCT. From January 2007 to December 2018 in Peking University People's Hospital, 6449 patients receiv...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0903-8

    authors: Cai X,Fu HX,Mo XD,Wang Y,Zhang YY,Wu J,Han W,Tang FF,Gui RY,Chen H,Chen Y,Zhao P,Yan CH,Wang JZ,Chen YH,Chang YJ,Xu LP,Liu KY,Huang XJ,Zhang XH

    更新日期:2020-11-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract::Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41409-019-0536-y

    authors: Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期:2019-11-01 00:00:00

  • Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.

    abstract::Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 10(6) CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage co...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701055

    authors: Schiller G,Vescio R,Freytes C,Spitzer G,Lee M,Wu CH,Cao J,Lee JC,Lichtenstein A,Lill M,Berenson R,Berenson J

    更新日期:1998-01-01 00:00:00

  • Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.

    abstract::Twenty-five patients with hematologic malignancies (n = 21) or aplastic anemia (n = 4) undergoing an allogeneic BMT from an HLA-identical sibling developed cytomegalovirus (CMV) antigenemia at a mean interval from BMT of 41 days (range 16-141 days). All patients were treated at the time of antigenemia in the absence o...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bacigalupo A,van Lint MT,Tedone E,Moro F,Sanna MA,Longren M,Trespi G,Frassoni F,Occhini D,Gualandi F

    更新日期:1994-06-01 00:00:00

  • Predictive value of flow cytometric analyses of blast cells in assessing the phenotype of the leukemia colony-forming cell (L-CFC) population in acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) blast cells (BC) express antigens that are commonly found on their normal counterparts. The leukemia colony-forming cell (L-CFC) subpopulation, identified by its ability to form leukemia colonies in vitro, is thought to be the stem cell population that produces BC. To ascertain the associa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Howell AL,Stukel TA,Bloomfield CD,Ball ED

    更新日期:1992-09-01 00:00:00

  • Pregnancy after bone marrow transplantation for severe aplastic anemia.

    abstract::Two women suffering from severe aplastic anemia were treated by bone marrow transplantation (BMT). They became pregnant 17 and 40 months after the procedure. During the first 20 weeks of pregnancy, one of them continued to receive cyclosporin A (CSA) to prevent graft-versus-host disease. Her CSA serum levels during th...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schmidt H,Ehninger G,Dopfer R,Waller HD

    更新日期:1987-10-01 00:00:00

  • Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

    abstract::High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703757

    authors: Thieblemont C,Dumontet C,Saad H,Roch N,Bouafia F,Arnaud P,Hequet O,Espinouse D,Salles G,Roy P,Eljaafari-Corbin A,Du Manoir-Baumgarten C,Coiffier B

    更新日期:2002-12-01 00:00:00

  • Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma.

    abstract::In an attempt to improve the dismal prognosis of adults with recurrent medulloblastoma, six patients were treated with aggressive salvage therapy including high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). At relapse, all patients underwent surgical debulking followed by HDCT/ASCT and then...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703725

    authors: Zia MI,Forsyth P,Chaudhry A,Russell J,Stewart DA

    更新日期:2002-11-01 00:00:00

  • Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers.

    abstract::Hematopoietic progenitor cell levels were monitored in the peripheral blood of ten healthy adults receiving a single dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The objective was to determine the time and number of progenitor cells released into the peripheral blood, induced by a single ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schwinger W,Mache C,Urban C,Beaufort F,Töglhofer W

    更新日期:1993-06-01 00:00:00

  • The evolution of clinical peripheral blood stem cell transplantation.

    abstract::Our growing physiological understanding of hematopoietic progenitor cells has led to the clinical use of circulating progenitor cells, including stem cells, for either reconstitution of hematopoietic function, up to the transduction of functional genes into a self-renewing cell system. In the following, an attempt has...

    journal_title:Bone marrow transplantation

    pub_type: 历史文章,杂志文章

    doi:

    authors: Körbling M,Fliedner TM

    更新日期:1996-05-01 00:00:00

  • FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.

    abstract::A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matche...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704172

    authors: Tanner ML,Hoh CK,Bashey A,Holman P,Sun C,Broome HE,Lane T,Ball ED,Carrier E

    更新日期:2003-09-01 00:00:00

  • Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

    abstract::In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.286

    authors: Robinson SP,Boumendil A,Finel H,Blaise D,Poiré X,Nicolas-Virelizier E,Or R,Malladi R,Corby A,Fornecker L,Caballero D,Pohlreich D,Nagler A,Thieblemont C,Finke J,Bachy E,Vincent L,Schroyens W,Schouten H,Dreger P

    更新日期:2016-03-01 00:00:00

  • Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?

    abstract::Clostridium difficile is the most common cause of nosocomial diarrhea in the United States and Europe, and is a cause of significant morbidity and mortality among hospitalized patients. A newly identified epidemic strain has been associated with many hospital outbreaks of C. difficile-associated disease (CDAD), raisin...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2008.317

    authors: Bobak D,Arfons LM,Creger RJ,Lazarus HM

    更新日期:2008-12-01 00:00:00

  • Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study.

    abstract::Acute graft-versus-host disease (aGVHD) is a frequent and major complication after allogeneic stem cell transplantation. For many years psoralen and ultraviolet (UV)-A light have been used in the treatment of chronic cutaneous graft-versus-host disease, but few patients have received PUVA therapy for aGVHD. We assesse...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701537

    authors: Wiesmann A,Weller A,Lischka G,Klingebiel T,Kanz L,Einsele H

    更新日期:1999-01-01 00:00:00

  • Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.

    abstract::Fifteen patients with stage II-III multiple myeloma were intended to undergo two sequential cycles of myeloablative chemoradiotherapy with autologous bone marrow or blood stem cell transplantation after response to primary induction chemotherapy. BM grafts were used in 13 of the 15 first transplants whereas PBSC were ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Björkstrand B,Ljungman P,Bird JM,Samson D,Gahrton G

    更新日期:1995-03-01 00:00:00

  • Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

    abstract::Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0298-y

    authors: Schechter T,Perez-Albuerne E,Lin TF,Irwin MS,Essa M,Desai AV,Frangoul H,Yanik G,Dupuis LL,Jacobsohn D,Kletzel M,Ranalli M,Soni S,Seif AE,Grupp S,Dvorak CC

    更新日期:2020-03-01 00:00:00

  • Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

    abstract::We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-al...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.320

    authors: Kim DY,Lee JH,Lee JH,Kim SH,Lim SN,Kim SD,Choi Y,Lee YS,Kang YA,Kang SI,Seol M,Ryu SG,Lee KH

    更新日期:2010-07-01 00:00:00

  • Clonal imbalances of serum immunoglobulins after allogeneic bone marrow transplantation: an analysis by high-resolution two-dimensional gel electrophoresis.

    abstract::The clonality pattern of immunoglobulins (Igs) produced after allogeneic bone marrow transplantation (BMT) was studied by high-resolution two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of serum samples and purified Igs. With this technique, the light (L) chain of a monoclonal Ig usually appears as a sing...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tissot JD,Helg C,Chapuis B,Zubler RH,Jeannet M,Hochstrasser DF,Hohlfeld P,Schneider P

    更新日期:1992-10-01 00:00:00

  • Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life.

    abstract::Quality of life (QOL) is increasingly recognized as an important clinical outcome of hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim of the current qualitative study was to examine education regarding post-HCT QOL from the patient's perspective. Allogeneic HCT recipients pa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.158

    authors: Jim HS,Quinn GP,Gwede CK,Cases MG,Barata A,Cessna J,Christie J,Gonzalez L,Koskan A,Pidala J

    更新日期:2014-02-01 00:00:00

  • The clinical value of biomarkers in respiratory complications in hematopoietic SCT.

    abstract::To determine the role of biomarkers in the clinical management of respiratory complications (RC) in hematopoietic stem cell transplantation (HSCT) recipients, we have prospectively evaluated a cohort of 175 patients followed-up for 1 year after HSCT. To avoid misinterpretation, we have excluded both unidentified respi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2016.280

    authors: Lucena CM,Rovira M,Gabarrús A,Filella X,Martínez C,Domingo R,Torres A,Agustí C

    更新日期:2017-03-01 00:00:00

  • Clinical effectiveness of hyperbaric oxygen therapy for BK-virus-associated hemorrhagic cystitis after allogeneic bone marrow transplantation.

    abstract::Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been associated with BK virus (BKV). Antiviral drugs are of limited efficacy and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients. We, therefore, retrosp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.228

    authors: Savva-Bordalo J,Pinho Vaz C,Sousa M,Branca R,Campilho F,Resende R,Baldaque I,Camacho O,Campos A

    更新日期:2012-08-01 00:00:00

  • Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.

    abstract::We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.258

    authors: Terwey TH,Massenkeil G,Tamm I,Hemmati PG,Neuburger S,Martus P,Dörken B,Hoelzer D,Arnold R

    更新日期:2008-12-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract::In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.193

    authors: Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期:2014-12-01 00:00:00

  • Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion.

    abstract::We retrospectively compared the incidence of acute graft-versus-host disease (GVHD) before and after September 1999, when we changed the mode of cyclosporine A (CsA) administration from twice-daily infusions (TD) (n=58) to continuous infusion (CIF) (n=71). The incidence of grade II-IV acute GVHD in the CIF group (56%)...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704374

    authors: Ogawa N,Kanda Y,Matsubara M,Asano Y,Nakagawa M,Sakata-Yanagimoto M,Kandabashi K,Izutsu K,Imai Y,Hangaishi A,Kurokawa M,Tsujino S,Ogawa S,Aoki K,Chiba S,Motokura T,Hirai H

    更新日期:2004-03-01 00:00:00

  • Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.

    abstract:SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704209

    authors: Dalle JH,Wall D,Theoret Y,Duval M,Shaw L,Larocque D,Taylor C,Gardiner J,Vachon MF,Champagne MA

    更新日期:2003-10-01 00:00:00

  • Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal.

    abstract::The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702043

    authors: Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

    更新日期:1999-12-01 00:00:00